Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2025)
Historic Retained Earnings for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$718.4 million.
- Amylyx Pharmaceuticals' Retained Earnings fell 2622.91% to -$718.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$718.4 million, marking a year-over-year decrease of 2622.91%. This contributed to the annual value of -$606.7 million for FY2024, which is 9894.87% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Retained Earnings of -$718.4 million as of Q3 2025, which was down 2622.91% from -$684.0 million recorded in Q2 2025.
- Amylyx Pharmaceuticals' Retained Earnings' 5-year high stood at -$155.8 million during Q4 2021, with a 5-year trough of -$718.4 million in Q3 2025.
- Moreover, its 5-year median value for Retained Earnings was -$353.4 million (2022), whereas its average is -$420.1 million.
- In the last 5 years, Amylyx Pharmaceuticals' Retained Earnings plummeted by 12728.99% in 2022 and then surged by 1390.97% in 2023.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Retained Earnings stood at -$155.8 million in 2021, then tumbled by 127.29% to -$354.2 million in 2022, then rose by 13.91% to -$304.9 million in 2023, then tumbled by 98.95% to -$606.7 million in 2024, then fell by 18.42% to -$718.4 million in 2025.
- Its Retained Earnings was -$718.4 million in Q3 2025, compared to -$684.0 million in Q2 2025 and -$642.6 million in Q1 2025.